GFO Issue 94, Article Number: 2
Sub-title :
ABSTRACT
ABSTRACT
An analysis conducted by GFO shows that half of all countries that are eligible to receive Global Fund grants currently provide ARV treatment to less than 25% of those that need it, and/or have at least 25,000 people who need ARV treatment but are not receiving it.
An analysis by GFO of data newly provided at www.GlobalHealthFacts.org (see previous article) shows that 62 of the 126 countries that are eligible to apply to the Global Fund (i.e. 48% of these countries) currently provide ARV treatment to less than 25% of those that need it, and/or have at least 25,000 people who need ARV treatment but are not receiving it.
This suggests that all of these countries, and probably many others, are urgently in need of scaling up treatment through support from the Global Fund or others.
The countries in question are those shown in bold in the following table. Further explanations are provided at the end of the table.
Country
(showing all countries eligible for Global Fund HIV grants)
People Living with HIV/AIDS
HIV Prevalence
People needing ARV treatment
People receiving ARV treatment
Of which:
People "needing" treatment minus people "receiving" treatment
Coverage
(equals "Receiving" as % of "Needing")
People receiving ARV treatment with GF support
People receiving ARV treatment with Pepfar support
Global
32,900,000
0.8%
9,700,000
2,990,000
1,447,976
1,641,000
6,710,000
31%
Afghanistan
NA
NA
NA
0
0
0
NA
NA
Albania
<1000
<0.2%
NA
<100
0
0
NA
NA
Algeria
21,000
0.1%
4,900
1,000
850
0
3,900
20%
Angola
190,000
2.1%
47,000
12,000
9,263
0
35,000
25%
Argentina
120,000
0.5%
53,000
38,000
0
0
15,000
73%
Armenia
2,400
0.1%
660
<100
59
0
c. 610
12%
Azerbaijan
7,800
0.2%
580
<100
24
0
c. 530
14%
Bangladesh
12,000
<0.1%
2,400
<200
0
0
c. 2,300
7%
Belarus
13,000
0.2%
4,300
900
643
0
3,400
20%
Belize
3,600
2.1%
1,100
600
494
0
500
49%
Benin
64,000
1.2%
20,000
9,800
8,633
0
10,200
49%
Bhutan
<500
0.1%
<100
<100
0
0
<100
NA
Bolivia
8,100
0.2%
2,300
<500
416
0
c. 2,050
22%
Bosnia and Herzegovina
<500
<0.1%
NA
<100
0
0
NA
NA
Botswana
300,000
23.9%
120,000
93,000
0
94,900
27,000
79%
Brazil
730,000
0.6%
230,000
181,000
0
0
49,000
80%
Bulgaria
NA
NA
NA
<500
210
0
NA
NA
Burkina Faso
130,000
1.6%
48,000
17,000
5,237
0
31,000
35%
Burundi
110,000
2.0%
47,000
11,000
8,935
0
36,000
23%
Cambodia
75,000
0.8%
40,000
27,000
23,587
0
13,000
67%
Cameroon
540,000
5.1%
180,000
46,000
28,773
0
134,000
25%
Cape Verde
NA
NA
NA
<500
0
0
NA
NA
Central African Republic
160,000
6.3%
45,000
9,600
4,801
0
35,400
21%
Chad
200,000
3.5%
55,000
7,400
1,430
0
47,600
13%
China
700,000
0.1%
190,000
35,000
28,884
0
155,000
19%
Colombia
170,000
0.6%
54,000
21,000
78
0
33,000
38%
Comoros
<200
<0.1%
<100
<100
5
0
<100
NA
Congo
79,000
3.5%
29,000
5,000
4,066
0
24,000
17%
Congo (DRC)
400,000-
500,000
1.2-1.5%
120,000
29,000
13,064
0
91,000
24%
Cote d'Ivoire
480,000
3.9%
190,000
52,000
46,007
39,700
138,000
28%
Cuba
6,200
0.1%
1,400
3,100
2,581
0
-1,700
>95%
Djibouti
16,000
3.1%
4,500
700
725
0
3,800
16%
Dominica
NA
NA
NA
<100
0
0
NA
NA
Dominican Rep.
62,000
1.1%
22,000
8,200
7,768
0
13,800
38%
Ecuador
26,000
0.3%
7,600
3,200
2,317
0
4,400
42%
Egypt
9,200
<0.1%
2,200
<500
0
0
c. 1,950
9%
El Salvador
35,000
0.8%
11,000
5,800
4,708
0
5,200
51%
Eritrea
38,000
1.3%
10,000
1,300
1,890
0
8,700
13%
Ethiopia
980,000
2.1%
310,000
90,000
81,819
97,100
220,000
29%
Fiji
<500
0.1%
<200
<100
0
0
c. 50
NA
Gabon
49,000
5.9%
15,000
6,400
3,306
0
8,600
42%
Gambia
8,200
0.9%
2,300
<500
385
0
c. 2,050
18%
Georgia
2,700
0.1%
<500
<500
271
0
<500
NA
Ghana
260,000
1.9%
87,000
13,000
10,275
0
74,000
15%
Grenada
NA
NA
NA
<100
0
0
NA
NA
Guatemala
59,000
0.8%
21,000
7,800
2,937
0
13,200
37%
Guinea
87,000
1.6%
21,000
5,700
1,411
0
15,300
27%
Guinea-Bissau
16,000
1.8%
4,400
900
517
0
3,500
20%
Guyana
13,000
2.5%
4,300
2,000
2,054
2,000
2,300
45%
Haiti
120,000
2.2%
36,000
15,000
12,921
15,100
21,000
41%
Honduras
28,000
0.7%
12,000
5,600
5,006
0
6,400
47%
India
2,400,000
0.3%
NA
158,000
100,897
0
NA
NA
Indonesia
270,000
0.2%
43,000
6,600
6,647
0
36,400
15%
Iran
86,000
0.2%
19,000
900
47
0
18,100
5%
Iraq
NA
<0.2%
NA
0
0
0
NA
NA
Jamaica
27,000
1.6%
8,500
3,600
4,000
0
4,900
43%
Jordan
<1000
<0.2%
NA
<100
45
0
NA
NA
Kazakhstan
12,000
0.1%
1,900
<500
342
0
c. 1,650
23%
Kenya
1,500,000-
2,000,000
7.1-8.5
470,000
177,000
166,379
192,100
293,000
38%
Kiribati
NA
NA
NA
<100
0
0
NA
NA
Korea (North)
<100
<0.1%
2,900
NA
0
0
<=2,900
0%
Kyrgyzstan
4,200
0.1%
610
<100
62
0
c. 560
14%
Lao PDR
5,500
0.2%
690
700
0
0
-10
>95%
Lesotho
270,000
23.2%
85,000
22,000
17,728
0
63,000
26%
Liberia
35,000
1.7%
8,500
1,400
1,157
0
7,100
17%
Macedonia
<500
<0.1%
NA
<100
20
0
NA
NA
Madagascar
14,000
0.1%
3,200
<200
163
0
c. 3,100
4%
Malawi
930,000
11.9%
290,000
101,000
79,398
0
189,000
35%
Malaysia
80,000
0.5%
20,000
6,800
0
0
13,200
35%
Maldives
<100
<0.1%
<100
<100
0
0
<100
NA
Mali
100,000
1.5%
30,000
12,000
12,814
0
18,000
41%
Marshall Islands
NA
NA
NA
<100
0
0
NA
NA
Mauritania
14,000
0.8%
3,600
800
531
0
2,800
23%
Mauritius
13,000
1.7%
1,500
<500
0
0
c. 1,250
22%
Mexico
200,000
0.3%
76,000
43,000
0
0
33,000
57%
Micronesia
NA
NA
NA
<100
0
0
NA
NA
Moldova
8,900
0.4%
800
<500
451
0
c. 550
58%
Mongolia
<1000
0.1%
<100
<100
2
0
<100
NA
Morocco
21,000
0.1%
5,300
1,600
1,400
0
3,700
31%
Mozambique
1,500,000
12.5%
370,000
90,000
78,236
88,200
280,000
24%
Myanmar
240,000
0.7%
76,000
11,000
0
0
65,000
15%
Namibia
200,000
15.3%
59,000
52,000
43,694
52,800
7,000
88%
Nepal
70,000
0.5%
20,000
1,400
1,240
0
18,600
7%
Nicaragua
7,700
0.2%
1,700
500
531
0
1,200
30%
Niger
60,000
0.8%
16,000
1,500
1,907
0
14,500
10%
Nigeria
2,600,000
3.1%
750,000
198,000
4,832
162,500
552,000
26%
Pakistan
96,000
0.1%
20,000
600
361
0
19,400
3%
Panama
20,000
1.0%
7,200
4,000
0
0
3,200
56%
Papua New Guinea
54,000
1.5%
5,900
2,300
1,546
0
3,600
38%
Paraguay
21,000
0.6%
4,800
1,100
0
0
3,700
22%
Peru
76,000
0.5%
23,000
11,000
10,610
0
12,000
48%
Philippines
8,300
<0.1%
1,100
<500
170
0
c. 850
31%
Rwanda
150,000
2.8%
68,000
49,000
44,395
52,400
19,000
71%
Saint Lucia
NA
NA
NA
<100
0
0
NA
NA
St. Vincent & Grenadines
NA
NA
NA
<100
0
0
NA
NA
Samoa
NA
NA
NA
<100
0
0
NA
NA
Sao Tome & Principe
NA
NA
NA
<100
0
0
NA
NA
Senegal
67,000
1.0%
12,000
6,700
2,270
0
5,300
56%
Serbia and Montenegro
6,400
0.1%
NA
NA
481
0
NA
NA
Sierra Leone
55,000
1.7%
13,000
2,600
1,623
0
10,400
20%
Solomon Islands
NA
NA
NA
<100
0
0
NA
NA
Somalia
24,000
0.5%
6,300
<500
201
0
c. 6,050
NA
South Africa
5,700,000
18.1%
1,700,000
460,000
115,142
435,100
1,240,000
28%
Sri Lanka
3,800
<0.1%
780
<200
0
0
c. 680
14%
Sudan
320,000
1.4%
87,000
1,200
1,480
0
85,800
1%
Suriname
6,800
2.4%
1,600
700
656
0
900
45%
Swaziland
190,000
26.1%
59,000
25,000
21,670
0
34,000
42%
Syria
NA
<0.2%
NA
<100
0
0
NA
NA
Tajikistan
10,000
0.3%
1,300
<100
94
0
c. 1,250
6%
Tanzania
1,400,000
6.2%
440,000
136,000
96,936
114,200
304,000
31%
Thailand
610,000
1.4%
250,000
153,000
93,839
0
97,000
61%
Timor Leste
NA
NA
NA
0
0
0
NA
NA
Togo
130,000
3.3%
41,000
8,000
3,389
0
33,000
19%
Tonga
NA
NA
NA
NA
0
0
NA
NA
Tunisia
3,700
0.1%
1,000
<500
0
0
c. 750
29%
Turkmenistan
<500
<0.1%
NA
0
0
0
NA
NA
Uganda
940,000
5.4%
350,000
115,000
46,642
131,200
235,000
33%
Ukraine
440,000
1.6%
91,000
7,700
4,060
0
83,300
8%
Uruguay
10,000
0.6%
3,100
1,800
0
0
1,300
56%
Uzbekistan
16,000
0.1%
1,400
<500
277
0
c. 1,150
24%
Vanuatu
NA
NA
NA
<100
0
0
NA
NA
Viet Nam
290,000
0.5%
67,000
17,000
2,927
11,800
50,000
26%
W. Bank & Gaza
NA
NA
NA
NA
0
0
NA
NA
Yemen
NA
<0.2%
NA
<200
0
0
NA
NA
Zambia
1,100,000
15.2%
330,000
151,000
122,684
151,900
179,000
46%
Zimbabwe
1,300,000
15.3%
570,000
98,000
8,634
0
472,000
17%
Technical notes:
- Further details regarding the columns are:
- Country:Â All countries that were eligible to apply for Global Fund HIV grants in Round 8.
- People Living with HIV/AIDS:Adults and children living with HIV/AIDS, 2007.
- HIV Prevalence:Â Percentage of adults who had HIV/AIDS in 2007.
- People needing ARV Treatment:Â Estimated number of people needing ARV treatment, 2007. (Note: ARV treatment is usually not needed until several years after infection with HIV.)
- People receiving ARV Treatment:Estimated number of people receiving ARV treatment, December 2007.
- People receiving ARV treatment with GF support:Â People receiving ARV treatment from programmes supported by the Global Fund, as of 1 Dec. 2007. (Original source:Â www.theglobalfund.org/en/files/publications/factsheets/aids/ARV_Factsheet_2007.pdf.)
- People receiving ARV treatment with Pepfar support:Â Number of people receiving ARV treatment from programmes supported by Pepfar, as of 31 March 2008.
- People "needing" treatment minus people "receiving" treatment:Â The difference between "people needing ARV Treatment" and "people receiving ARV Treatment".
- Coverage:Â Those "receiving" as a percentage of those "needing", December 2007.
- The number in the GF column or in the Pepfar column sometimes exceeds the total number shown for people nationwide treatment, because of data being gathered at different points during 2007.
- Countries are shown in bold in cases where Coverage is less than 25%, and/or where people "needing" treatment minus people "receiving" treatment is greater than 25,000 people.
- It should be noted that the people shown as needing but not yet receiving treatment will not be known to themselves or to anyone else if they have not been tested and are not yet symptomatic. And even if such people are known, the country may need to invest in health systems before such treatment can be provided.
- All data were obtained in August 2008 from www.GlobalHealthFacts.org, a website created by the Kaiser Family Foundation. Data provided at this site are primarily obtained from the Global Fund, UN agencies, Pepfar and other international entities, rather than from individual implementing countries, and therefore do not always represent the most recent data available at the country level.
- A more detailed spreadsheet-based version of this analysis, compiled by Aidspan in the course of writing this article, is available at www.aidspan.org/documents/other/Aidspan-ARV-numbers-analysis.xls.
- In countries where the Global Fund (or Pepfar) provides substantial support on a national scale for things like clinics, testing facilities, and distribution and logistics systems, the Fund (or Pepfar, as the case may be) sometimes publishes numbers (reproduced in the relevant columns of the above table) stating that all people in the country who are receiving treatment are doing so with GF/Pepfar support. Thus, for most countries, the numbers in these two columns overlap substantially if not entirely. (This point is discussed further in the Commentary, below.)
|
Country (showing all countries eligible for Global Fund HIV grants) |
People Living with HIV/AIDS |
HIV Prevalence |
People needing ARV treatment |
People receiving ARV treatment |
Of which: |
People "needing" treatment minus people "receiving" treatment |
Coverage (equals "Receiving" as % of "Needing") |
|
|
People receiving ARV treatment with GF support |
People receiving ARV treatment with Pepfar support |
|||||||
| Global |
32,900,000 |
0.8% |
9,700,000 |
2,990,000 |
1,447,976 |
1,641,000 |
6,710,000 |
31% |
| Afghanistan |
NA |
NA |
NA |
0 |
0 |
0 |
NA |
NA |
| Albania |
<1000 |
<0.2% |
NA |
<100 |
0 |
0 |
NA |
NA |
| Algeria |
21,000 |
0.1% |
4,900 |
1,000 |
850 |
0 |
3,900 |
20% |
| Angola |
190,000 |
2.1% |
47,000 |
12,000 |
9,263 |
0 |
35,000 |
25% |
| Argentina |
120,000 |
0.5% |
53,000 |
38,000 |
0 |
0 |
15,000 |
73% |
| Armenia |
2,400 |
0.1% |
660 |
<100 |
59 |
0 |
c. 610 |
12% |
| Azerbaijan |
7,800 |
0.2% |
580 |
<100 |
24 |
0 |
c. 530 |
14% |
| Bangladesh |
12,000 |
<0.1% |
2,400 |
<200 |
0 |
0 |
c. 2,300 |
7% |
| Belarus |
13,000 |
0.2% |
4,300 |
900 |
643 |
0 |
3,400 |
20% |
| Belize |
3,600 |
2.1% |
1,100 |
600 |
494 |
0 |
500 |
49% |
| Benin |
64,000 |
1.2% |
20,000 |
9,800 |
8,633 |
0 |
10,200 |
49% |
| Bhutan |
<500 |
0.1% |
<100 |
<100 |
0 |
0 |
<100 |
NA |
| Bolivia |
8,100 |
0.2% |
2,300 |
<500 |
416 |
0 |
c. 2,050 |
22% |
| Bosnia and Herzegovina |
<500 |
<0.1% |
NA |
<100 |
0 |
0 |
NA |
NA |
| Botswana |
300,000 |
23.9% |
120,000 |
93,000 |
0 |
94,900 |
27,000 |
79% |
| Brazil |
730,000 |
0.6% |
230,000 |
181,000 |
0 |
0 |
49,000 |
80% |
| Bulgaria |
NA |
NA |
NA |
<500 |
210 |
0 |
NA |
NA |
| Burkina Faso |
130,000 |
1.6% |
48,000 |
17,000 |
5,237 |
0 |
31,000 |
35% |
| Burundi |
110,000 |
2.0% |
47,000 |
11,000 |
8,935 |
0 |
36,000 |
23% |
| Cambodia |
75,000 |
0.8% |
40,000 |
27,000 |
23,587 |
0 |
13,000 |
67% |
| Cameroon |
540,000 |
5.1% |
180,000 |
46,000 |
28,773 |
0 |
134,000 |
25% |
| Cape Verde |
NA |
NA |
NA |
<500 |
0 |
0 |
NA |
NA |
| Central African Republic |
160,000 |
6.3% |
45,000 |
9,600 |
4,801 |
0 |
35,400 |
21% |
| Chad |
200,000 |
3.5% |
55,000 |
7,400 |
1,430 |
0 |
47,600 |
13% |
| China |
700,000 |
0.1% |
190,000 |
35,000 |
28,884 |
0 |
155,000 |
19% |
| Colombia |
170,000 |
0.6% |
54,000 |
21,000 |
78 |
0 |
33,000 |
38% |
| Comoros |
<200 |
<0.1% |
<100 |
<100 |
5 |
0 |
<100 |
NA |
| Congo |
79,000 |
3.5% |
29,000 |
5,000 |
4,066 |
0 |
24,000 |
17% |
| Congo (DRC) |
400,000- 500,000 |
1.2-1.5% |
120,000 |
29,000 |
13,064 |
0 |
91,000 |
24% |
| Cote d'Ivoire |
480,000 |
3.9% |
190,000 |
52,000 |
46,007 |
39,700 |
138,000 |
28% |
| Cuba |
6,200 |
0.1% |
1,400 |
3,100 |
2,581 |
0 |
-1,700 |
>95% |
| Djibouti |
16,000 |
3.1% |
4,500 |
700 |
725 |
0 |
3,800 |
16% |
| Dominica |
NA |
NA |
NA |
<100 |
0 |
0 |
NA |
NA |
| Dominican Rep. |
62,000 |
1.1% |
22,000 |
8,200 |
7,768 |
0 |
13,800 |
38% |
| Ecuador |
26,000 |
0.3% |
7,600 |
3,200 |
2,317 |
0 |
4,400 |
42% |
| Egypt |
9,200 |
<0.1% |
2,200 |
<500 |
0 |
0 |
c. 1,950 |
9% |
| El Salvador |
35,000 |
0.8% |
11,000 |
5,800 |
4,708 |
0 |
5,200 |
51% |
| Eritrea |
38,000 |
1.3% |
10,000 |
1,300 |
1,890 |
0 |
8,700 |
13% |
| Ethiopia |
980,000 |
2.1% |
310,000 |
90,000 |
81,819 |
97,100 |
220,000 |
29% |
| Fiji |
<500 |
0.1% |
<200 |
<100 |
0 |
0 |
c. 50 |
NA |
| Gabon |
49,000 |
5.9% |
15,000 |
6,400 |
3,306 |
0 |
8,600 |
42% |
| Gambia |
8,200 |
0.9% |
2,300 |
<500 |
385 |
0 |
c. 2,050 |
18% |
| Georgia |
2,700 |
0.1% |
<500 |
<500 |
271 |
0 |
<500 |
NA |
| Ghana |
260,000 |
1.9% |
87,000 |
13,000 |
10,275 |
0 |
74,000 |
15% |
| Grenada |
NA |
NA |
NA |
<100 |
0 |
0 |
NA |
NA |
| Guatemala |
59,000 |
0.8% |
21,000 |
7,800 |
2,937 |
0 |
13,200 |
37% |
| Guinea |
87,000 |
1.6% |
21,000 |
5,700 |
1,411 |
0 |
15,300 |
27% |
| Guinea-Bissau |
16,000 |
1.8% |
4,400 |
900 |
517 |
0 |
3,500 |
20% |
| Guyana |
13,000 |
2.5% |
4,300 |
2,000 |
2,054 |
2,000 |
2,300 |
45% |
| Haiti |
120,000 |
2.2% |
36,000 |
15,000 |
12,921 |
15,100 |
21,000 |
41% |
| Honduras |
28,000 |
0.7% |
12,000 |
5,600 |
5,006 |
0 |
6,400 |
47% |
| India |
2,400,000 |
0.3% |
NA |
158,000 |
100,897 |
0 |
NA |
NA |
| Indonesia |
270,000 |
0.2% |
43,000 |
6,600 |
6,647 |
0 |
36,400 |
15% |
| Iran |
86,000 |
0.2% |
19,000 |
900 |
47 |
0 |
18,100 |
5% |
| Iraq |
NA |
<0.2% |
NA |
0 |
0 |
0 |
NA |
NA |
| Jamaica |
27,000 |
1.6% |
8,500 |
3,600 |
4,000 |
0 |
4,900 |
43% |
| Jordan |
<1000 |
<0.2% |
NA |
<100 |
45 |
0 |
NA |
NA |
| Kazakhstan |
12,000 |
0.1% |
1,900 |
<500 |
342 |
0 |
c. 1,650 |
23% |
| Kenya |
1,500,000- 2,000,000 |
7.1-8.5 |
470,000 |
177,000 |
166,379 |
192,100 |
293,000 |
38% |
| Kiribati |
NA |
NA |
NA |
<100 |
0 |
0 |
NA |
NA |
| Korea (North) |
<100 |
<0.1% |
2,900 |
NA |
0 |
0 |
<=2,900 |
0% |
| Kyrgyzstan |
4,200 |
0.1% |
610 |
<100 |
62 |
0 |
c. 560 |
14% |
| Lao PDR |
5,500 |
0.2% |
690 |
700 |
0 |
0 |
-10 |
>95% |
| Lesotho |
270,000 |
23.2% |
85,000 |
22,000 |
17,728 |
0 |
63,000 |
26% |
| Liberia |
35,000 |
1.7% |
8,500 |
1,400 |
1,157 |
0 |
7,100 |
17% |
| Macedonia |
<500 |
<0.1% |
NA |
<100 |
20 |
0 |
NA |
NA |
| Madagascar |
14,000 |
0.1% |
3,200 |
<200 |
163 |
0 |
c. 3,100 |
4% |
| Malawi |
930,000 |
11.9% |
290,000 |
101,000 |
79,398 |
0 |
189,000 |
35% |
| Malaysia |
80,000 |
0.5% |
20,000 |
6,800 |
0 |
0 |
13,200 |
35% |
| Maldives |
<100 |
<0.1% |
<100 |
<100 |
0 |
0 |
<100 |
NA |
| Mali |
100,000 |
1.5% |
30,000 |
12,000 |
12,814 |
0 |
18,000 |
41% |
| Marshall Islands |
NA |
NA |
NA |
<100 |
0 |
0 |
NA |
NA |
| Mauritania |
14,000 |
0.8% |
3,600 |
800 |
531 |
0 |
2,800 |
23% |
| Mauritius |
13,000 |
1.7% |
1,500 |
<500 |
0 |
0 |
c. 1,250 |
22% |
| Mexico |
200,000 |
0.3% |
76,000 |
43,000 |
0 |
0 |
33,000 |
57% |
| Micronesia |
NA |
NA |
NA |
<100 |
0 |
0 |
NA |
NA |
| Moldova |
8,900 |
0.4% |
800 |
<500 |
451 |
0 |
c. 550 |
58% |
| Mongolia |
<1000 |
0.1% |
<100 |
<100 |
2 |
0 |
<100 |
NA |
| Morocco |
21,000 |
0.1% |
5,300 |
1,600 |
1,400 |
0 |
3,700 |
31% |
| Mozambique |
1,500,000 |
12.5% |
370,000 |
90,000 |
78,236 |
88,200 |
280,000 |
24% |
| Myanmar |
240,000 |
0.7% |
76,000 |
11,000 |
0 |
0 |
65,000 |
15% |
| Namibia |
200,000 |
15.3% |
59,000 |
52,000 |
43,694 |
52,800 |
7,000 |
88% |
| Nepal |
70,000 |
0.5% |
20,000 |
1,400 |
1,240 |
0 |
18,600 |
7% |
| Nicaragua |
7,700 |
0.2% |
1,700 |
500 |
531 |
0 |
1,200 |
30% |
| Niger |
60,000 |
0.8% |
16,000 |
1,500 |
1,907 |
0 |
14,500 |
10% |
| Nigeria |
2,600,000 |
3.1% |
750,000 |
198,000 |
4,832 |
162,500 |
552,000 |
26% |
| Pakistan |
96,000 |
0.1% |
20,000 |
600 |
361 |
0 |
19,400 |
3% |
| Panama |
20,000 |
1.0% |
7,200 |
4,000 |
0 |
0 |
3,200 |
56% |
| Papua New Guinea |
54,000 |
1.5% |
5,900 |
2,300 |
1,546 |
0 |
3,600 |
38% |
| Paraguay |
21,000 |
0.6% |
4,800 |
1,100 |
0 |
0 |
3,700 |
22% |
| Peru |
76,000 |
0.5% |
23,000 |
11,000 |
10,610 |
0 |
12,000 |
48% |
| Philippines |
8,300 |
<0.1% |
1,100 |
<500 |
170 |
0 |
c. 850 |
31% |
| Rwanda |
150,000 |
2.8% |
68,000 |
49,000 |
44,395 |
52,400 |
19,000 |
71% |
| Saint Lucia |
NA |
NA |
NA |
<100 |
0 |
0 |
NA |
NA |
| St. Vincent & Grenadines |
NA |
NA |
NA |
<100 |
0 |
0 |
NA |
NA |
| Samoa |
NA |
NA |
NA |
<100 |
0 |
0 |
NA |
NA |
| Sao Tome & Principe |
NA |
NA |
NA |
<100 |
0 |
0 |
NA |
NA |
| Senegal |
67,000 |
1.0% |
12,000 |
6,700 |
2,270 |
0 |
5,300 |
56% |
| Serbia and Montenegro |
6,400 |
0.1% |
NA |
NA |
481 |
0 |
NA |
NA |
| Sierra Leone |
55,000 |
1.7% |
13,000 |
2,600 |
1,623 |
0 |
10,400 |
20% |
| Solomon Islands |
NA |
NA |
NA |
<100 |
0 |
0 |
NA |
NA |
| Somalia |
24,000 |
0.5% |
6,300 |
<500 |
201 |
0 |
c. 6,050 |
NA |
| South Africa |
5,700,000 |
18.1% |
1,700,000 |
460,000 |
115,142 |
435,100 |
1,240,000 |
28% |
| Sri Lanka |
3,800 |
<0.1% |
780 |
<200 |
0 |
0 |
c. 680 |
14% |
| Sudan |
320,000 |
1.4% |
87,000 |
1,200 |
1,480 |
0 |
85,800 |
1% |
| Suriname |
6,800 |
2.4% |
1,600 |
700 |
656 |
0 |
900 |
45% |
| Swaziland |
190,000 |
26.1% |
59,000 |
25,000 |
21,670 |
0 |
34,000 |
42% |
| Syria |
NA |
<0.2% |
NA |
<100 |
0 |
0 |
NA |
NA |
| Tajikistan |
10,000 |
0.3% |
1,300 |
<100 |
94 |
0 |
c. 1,250 |
6% |
| Tanzania |
1,400,000 |
6.2% |
440,000 |
136,000 |
96,936 |
114,200 |
304,000 |
31% |
| Thailand |
610,000 |
1.4% |
250,000 |
153,000 |
93,839 |
0 |
97,000 |
61% |
| Timor Leste |
NA |
NA |
NA |
0 |
0 |
0 |
NA |
NA |
| Togo |
130,000 |
3.3% |
41,000 |
8,000 |
3,389 |
0 |
33,000 |
19% |
| Tonga |
NA |
NA |
NA |
NA |
0 |
0 |
NA |
NA |
| Tunisia |
3,700 |
0.1% |
1,000 |
<500 |
0 |
0 |
c. 750 |
29% |
| Turkmenistan |
<500 |
<0.1% |
NA |
0 |
0 |
0 |
NA |
NA |
| Uganda |
940,000 |
5.4% |
350,000 |
115,000 |
46,642 |
131,200 |
235,000 |
33% |
| Ukraine |
440,000 |
1.6% |
91,000 |
7,700 |
4,060 |
0 |
83,300 |
8% |
| Uruguay |
10,000 |
0.6% |
3,100 |
1,800 |
0 |
0 |
1,300 |
56% |
| Uzbekistan |
16,000 |
0.1% |
1,400 |
<500 |
277 |
0 |
c. 1,150 |
24% |
| Vanuatu |
NA |
NA |
NA |
<100 |
0 |
0 |
NA |
NA |
| Viet Nam |
290,000 |
0.5% |
67,000 |
17,000 |
2,927 |
11,800 |
50,000 |
26% |
| W. Bank & Gaza |
NA |
NA |
NA |
NA |
0 |
0 |
NA |
NA |
| Yemen |
NA |
<0.2% |
NA |
<200 |
0 |
0 |
NA |
NA |
| Zambia |
1,100,000 |
15.2% |
330,000 |
151,000 |
122,684 |
151,900 |
179,000 |
46% |
| Zimbabwe |
1,300,000 |
15.3% |
570,000 |
98,000 |
8,634 |
0 |
472,000 |
17% |
Technical notes:
- Further details regarding the columns are:
- Country:Â All countries that were eligible to apply for Global Fund HIV grants in Round 8.
- People Living with HIV/AIDS:Adults and children living with HIV/AIDS, 2007.
- HIV Prevalence:Â Percentage of adults who had HIV/AIDS in 2007.
- People needing ARV Treatment:Â Estimated number of people needing ARV treatment, 2007. (Note: ARV treatment is usually not needed until several years after infection with HIV.)
- People receiving ARV Treatment:Estimated number of people receiving ARV treatment, December 2007.
- People receiving ARV treatment with GF support:Â People receiving ARV treatment from programmes supported by the Global Fund, as of 1 Dec. 2007. (Original source:Â www.theglobalfund.org/en/files/publications/factsheets/aids/ARV_Factsheet_2007.pdf.)
- People receiving ARV treatment with Pepfar support:Â Number of people receiving ARV treatment from programmes supported by Pepfar, as of 31 March 2008.
- People "needing" treatment minus people "receiving" treatment:Â The difference between "people needing ARV Treatment" and "people receiving ARV Treatment".
- Coverage:Â Those "receiving" as a percentage of those "needing", December 2007.
- The number in the GF column or in the Pepfar column sometimes exceeds the total number shown for people nationwide treatment, because of data being gathered at different points during 2007.
- Countries are shown in bold in cases where Coverage is less than 25%, and/or where people "needing" treatment minus people "receiving" treatment is greater than 25,000 people.
- It should be noted that the people shown as needing but not yet receiving treatment will not be known to themselves or to anyone else if they have not been tested and are not yet symptomatic. And even if such people are known, the country may need to invest in health systems before such treatment can be provided.
- All data were obtained in August 2008 from www.GlobalHealthFacts.org, a website created by the Kaiser Family Foundation. Data provided at this site are primarily obtained from the Global Fund, UN agencies, Pepfar and other international entities, rather than from individual implementing countries, and therefore do not always represent the most recent data available at the country level.
- A more detailed spreadsheet-based version of this analysis, compiled by Aidspan in the course of writing this article, is available at www.aidspan.org/documents/other/Aidspan-ARV-numbers-analysis.xls.
- In countries where the Global Fund (or Pepfar) provides substantial support on a national scale for things like clinics, testing facilities, and distribution and logistics systems, the Fund (or Pepfar, as the case may be) sometimes publishes numbers (reproduced in the relevant columns of the above table) stating that all people in the country who are receiving treatment are doing so with GF/Pepfar support. Thus, for most countries, the numbers in these two columns overlap substantially if not entirely. (This point is discussed further in the Commentary, below.)
